Micron completes tens of millions in Pre-A+ round to advance microfluidic manufacturing industrialization

Recently, Sichuan Micron Biotechnology, a company specializing in intelligent microfluidic manufacturing technology, has completed a Pre-A+ funding round amounting to tens of millions of RMB. This round was invested by BioTrack Capital. The proceeds will accelerate the company's technology development and clinical programs, providing strong momentum for Micron's industrialization journey in the field of microfluidic technology.

Micron has established several pioneering theories for preparing functional microspheres using microfluidic technology. It has revolutionized fluid manipulation strategies in confined spaces, developed novel chip design and development methodologies, and innovatively adopted both closed and open amplification systems to create a batch production platform for microspheres. These advancements have successfully enabled the controllable preparation of over a hundred types of functional microspheres.

The company originated from the Laboratory of Membrane Science and Functional Materials at Sichuan University, translating nearly two decades of the laboratory's foundational research in microfluidic microsphere preparation into industrial practice.

Microfluidic technology, leveraging its precise fluid control capabilities at the micro- and nano-scale, enables exceptional uniformity in size, tunability in structure, customizable functionality, and linear scalability in production. Micron has focused its applications on drug delivery and medical devices, while also establishing an advanced microsphere materials pilot platform. This initiative extends the application of intelligent microfluidic manufacturing technology to broader scenarios, driving continuous innovation and development in precision medicine and intelligent manufacturing.

Following the completion of this new funding round, Micron will further intensify its R&D efforts, accelerate clinical validation stages, and optimize its market entry strategy.

Zhang Chuan, Founder of Micron, stated: "We extend our gratitude to BioTrack Capital for their recognition and support. Micron is a technology commercialization enterprise built upon the microfluidic manufacturing technology developed at Sichuan University. We are consistently committed to developing breakthrough products through groundbreaking technology. Our intelligent microfluidic manufacturing platform enables the precise preparation of microsphere products, truly realizing the vision of precision medicine. Simultaneously, we will accelerate the deployment of this platform technology across other application scenarios, ultimately achieving our vision of 'Micron Inside'."